Fig. 5

MerTK ASO modulates the expression of immune-related genes in the secondary tumors. A Scores of various immune pathways in the secondary tumors of the mice treated with XRT+MerTK, XRT+αPD1, XRT+αCTLA4, RPM, and RCM. B Changes in expression of genes in adaptive pathway, innate pathway, and T cell function of XRT+αPD1+MerTK in relative to XRT+αPD1. C Changes in expression of genes in adaptive pathway, innate pathway, and T cell function of XRT+αCTLA4+MerTK in relative to XRT+αCTLA4. The mice (n=3) were treated with different combinations of XRT, MerTK ASO, αPD1, and αCTLA4, as indicated in Fig. 1A and Fig. 2A, and were sacrificed on day 16. The total RNA extracted from the secondary tumors was analyzed with a nCounter PanCancer Immune Profiling Panel. All the statistics were compared with two-tailed t tests and expressed as mean value ± SEM. P values of <0.05 indicates statistical significance. *P<0.05, **P<0.01, NS denotes significant. All statistics were done using two-tailed t tests and expressed as mean value ± SEM. P values of <0.05 indicates statistical significance. *P<0.05, **P<0.01, ***P<0.001, NS denotes not significant